Analystreport

Iterum Therapeutics plc (NASDAQ: ITRM) was upgraded by analysts at HC Wainwright from a "neutral" rating to a "buy" rating. They now have a $6.00 price target on the stock.

Iterum Therapeutics plc - Ordinary Share  (ITRM) 
Last iterum therapeutics plc - ordinary share earnings: 11/12 04:30 pm Check Earnings Report